Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

BACKGROUND: Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Brempelis, Katherine J, Cowan, Courtney M, Kreuser, Shannon A, Labadie, Kevin P, Prieskorn, Brooke M, Lieberman, Nicole A P, Ene, Chibawanye I, Moyes, Kara W, Chinn, Harrison, DeGolier, Kole R, Matsumoto, Lisa R, Daniel, Sara K, Yokoyama, Jason K, Davis, Amira D, Hoglund, Virginia J, Smythe, Kimberly S, Balcaitis, Stephanie D, Jensen, Michael C, Ellenbogen, Richard G, Campbell, Jean S, Pierce, Robert H, Holland, Eric C, Pillarisetty, Venu G, Crane, Courtney A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594542/
https://www.ncbi.nlm.nih.gov/pubmed/33115946
http://dx.doi.org/10.1136/jitc-2020-001356

Ejemplares similares

Ejemplares similares